Finavestane A 360 B

Hazard statements

This product is classified as: Non-Hazardous according to the criteria of SWA. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. Not Hazardous – No criteria found

Precautionary statements

S23, S25. Do not breathe vapours or mists. Avoid contact with eyes

SUSMP Classification

None allocated

ADG classification

None allocated. Not a Dangerous Good under the ADG Code

UN Number

None allocated

Potential health effects

Inhalation - Short Term Exposure: Available data indicates that this product is not harmful. However product may be mildly irritating, although unlikely to cause anything more than mild transient discomfort. - Long Term Exposure: No data for health effects associated with long term inhalation. Skin Contact - Short Term Exposure: Available data indicates that this product is not harmful. It should present no hazards in normal use. In addition product is unlikely to cause any discomfort in normal use. - Long Term Exposure: No data for health effects associated with long term skin exposure. Eye Contact - Short Term Exposure: This product may be mildly irritating to eyes, but is unlikely to cause anything more than mild discomfort which should disappear once product is removed. - Long Term Exposure: No data for health effects associated with long term eye exposure. Ingestion - Short Term Exposure: Significant oral exposure is considered to be unlikely. This product is unlikely to cause any irritation problems in the short or long term. - Long Term Exposure: No data for health effects associated with long term ingestion. - Carcinogen Status: - SWA: No significant ingredient is classified as carcinogenic by SWA. - NTP: No significant ingredient is classified as carcinogenic by NTP. - IARC: No significant ingredient is classified as carcinogenic by IARC.